A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: Evidence for efficacy and high incidence of biological autoimmunity

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 329-336

  Poulalhon, N ^a   Begon, E ^a   Lebbe C ^a   Liote F ^b   Lahfa, M ^a   Bengoufa, D ^a   Morel, P ^a   Dubertret, L ^a   Bachelez, H ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Universit de Paris 7   (France)

Author keywords

Autoimmunity; Infliximab; Lupus erythematosus; Psoriasis; Pustular psoriasis; Tumour necrosis factor

Indexed keywords

ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE;

ACUTE RESPIRATORY TRACT DISEASE; ADULT; ANALYTIC METHOD; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; CANCER RECURRENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL STUDY; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHRODERMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GLOMUS TUMOR; HUMAN; IMMUNOFLUORESCENCE; INCIDENCE; INFECTION COMPLICATION; LIVER DISEASE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RASH; RHEUMATIC DISEASE; SCORING SYSTEM; SKIN TUMOR;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33846185076     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07639.x     Document Type: Article

References (41)

1. Boyman O, Hefti HP, Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T-cells and tumor necrosis factor-a. J Exp Med 2004; 199:731-6.
2. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-7.
3. Gottlieb AB, Chaudhari U, Mulcahy LD et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48:829-35.
4. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534-42.
5. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367-74.
6. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227-36.
7. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 2004; 15:280-94.
8. Colombel JF, Loftus EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126:19-31.
9. Benucci M, Li Gobbi F, Fossi F et al. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol 2005; 11:47-9.
10. Stokes MB, Foster K, Markowitz GS et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20:1400-6.
11. De Bandt M, Sibilia J, Le Loët X et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7:R545-51.
12. Atzeni F, Turiel M, Capsoni F et al. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci 2005; 1051:559-69.
13. De Rycke L, Kruithof E, van Damme N et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48:1015-23.
14. Ferraro-Peyret C, Coury F, Tebib JG et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6:R535-43.
15. Allanore Y, Sellam J, Batteux F et al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheum 2004; 22:756-8.
16. Eriksson C, Engstrand S, Sundqvist KG et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64:403-7.
17. De Rycke L, Baeten D, Kruithof E et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52:2192-201.
18. Caramaschi P, Biasi D, Colombatti M et al. Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006; 26:209-14.
19. Comby E, Tanaff P, Mariotte D et al. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol 2006; 33:24-30.
20. Elkayam O, Burke M, Vardinon N et al. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 2005; 38:155-60.
21. Jonsdottir T, Forslid J, van Vollenhoven A et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004; 63:1075-8.
22. Garcia-Planella E, Domenech E, Esteve-Comas M et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFα antibodies (infliximab). Eur J Gastroenterol Hepatol 2003; 15:351-4.
23. Vermeire S, Noman M, van Assche G et al. Autoimmunity associated with anti-tumor necrosis factor a treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125:32-9.
24. Atzeni F, Ardizzone S, Sarzi-Puttini P et al. Autoantibody profile during short term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther 2005; 22:453-61.
25. Nancey S, Blanvillain E, Parmentier B et al. Infliximab treatment does not induce organ-specific auto-antibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 2005; 11:986-91.
26. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
27. Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (Remicade). Int J Clin Pract 2001; 55:211-16.
28. Braun J, de Keyser F, Brandt J. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001; 13:245-9.
29. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153:486-97.
30. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000; 53:424-32.
31. Bootsma H, Spronk PE, Hummel EJ et al. Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996; 25:352-9.
32. Sellam J, Allanore Y, Batteux F et al. Autoantibody induction in patients with refractory spondylarthropathy treated with infliximab and methotrexate. Joint Bone Spine 2005; 72:48-52.
33. D'Auria F, Rovere-Querini P, Giazzon M et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 2004; 255:409-18.
34. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002; 61:358-61.
35. Krishnan RS, Hsu S. Serum sickness due to infliximab in a patient with psoriasis. J Drugs Dermatol 2004; 3:305-8.
36. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy in Crohn's disease. N Engl J Med 2003; 348:601-8.
37. Kugathasan S, Levy MB, Saeian K et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Inflamm Bowel Dis 2001; 7:34-7.
38. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med 2006; 30:41-4.
39. Chan JJ, Gebauer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous anti tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol 2003; 44:116-20.
40. Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 2004; 8:224-8.
41. Benoit S, Toksoy A, Brocker EB et al. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004; 150:1009-12.